Sinonasal Squamous Cell Carcinoma Outcomes: Does Treatment at a High-Volume Center Confer Survival Benefit?

Teitelbaum, Jordan I; Issa, Khalil; Ackall, Feras Y.; Jung, Sin‐Ho; Jang, David W.; Abi-Hachem, Ralph

doi:10.1055/s-0040-1702314

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A growing body of literature supports a positive association between hospital case volume and treatment outcomes for a variety of malignancies. [5][6][7][8][9][10][11][28][29][30][31][32][33] Importantly, volume itself does not drive outcomes but acts as a proxy for underlying factors more directly linked to quality of care. 25 For example, HVFs tend to show greater adherence to evidence-based guidelines, utilize advanced multidisciplinary care teams with specialized expertise, and have access to novel technologies and therapeutics.…”

Section: Discussionmentioning

confidence: 99%

“…A growing body of literature supports a positive association between hospital case volume and treatment outcomes for a variety of malignancies 5–11,28–33 . Importantly, volume itself does not drive outcomes but acts as a proxy for underlying factors more directly linked to quality of care 25 .…”

Section: Discussionmentioning

confidence: 99%

“…Populationbased analyses have reported a positive association between case volume and treatment outcomes for pathologies as diverse as testicular cancer, 5 nonsmall cell lung cancer, 6 nasopharyngeal carcinoma, 7 and head and neck (HN) squamous cell carcinoma, 8 among others. 9,10 Previous studies have demonstrated that facility case load predicts overall survival (OS) in cutaneous melanoma in general. 11,12 However, these relationships have not been evaluated in melanoma of the HN.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Case volume regionalization and volume‐based outcome differences in cutaneous head and neck melanoma

et al. 2022

View full text Add to dashboard Cite

Background Hospital volume has emerged as a prognostic factor in oncology but is not currently known whether volume is associated with improved outcomes for cutaneous head and neck (HN) melanoma. Methods A total of 556 079 cutaneous melanoma cases reported by the 2004–2016 National Cancer Database were separated into two cohorts (HN and non‐HN) and facilities within each cohort were classified by case volume. Analysis employed chi‐square, analysis of variance, Kaplan–Meier, and Cox proportional hazards models. Results Only 41 facilities (3.1% of 1326) treating HN melanoma and 50 facilities (3.7% of 1344) treating non‐HN melanoma were classified as high‐volume facilities (HVFs). The estimated 5‐year overall survival (OS) was 62.7% (standard error [SE]: 0.4%) for patients with HN at low‐volume facilities (LVFs), 69.3% (SE: 0.4%) at IVFs, and 71.8% (SE 0.4%) at HVFs (p < 0.001). Differences in OS remained significant between HVFs versus LVFs after adjusting for confounders. Conclusion Volume is independently associated with OS and improved surgical outcomes for HN melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Case volume regionalization and volume‐based outcome differences in cutaneous head and neck melanoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…While surgery is the mainstay of treatment in all histologies, achieving wide surgical resection with clear margins is a challenge. Resection is feasible in about 75% of sinonasal neoplasms [ 5 , 6 ] and only 53% of sinonasal squamous cell carcinomas [ 7 , 8 ]. Radiotherapy is thus usually indicated as a definitive exclusive treatment (generally with concomitant chemotherapy) when tumors are not resectable and as an adjuvant modality following surgery to optimize local control.…”

Section: Introductionmentioning

confidence: 99%

“…Radiotherapy is thus usually indicated as a definitive exclusive treatment (generally with concomitant chemotherapy) when tumors are not resectable and as an adjuvant modality following surgery to optimize local control. Sinonasal tumors are indeed an example of multidisciplinarity and should be best performed at high volume centers [ 8 , 9 ] ( Figure 1 ). The multidimensionality of the decision-making process is best demonstrated in borderline situations.…”

Section: Introductionmentioning

confidence: 99%

Precision Postoperative Radiotherapy in Sinonasal Carcinomas after Endonasal Endoscopic Surgery

Thariat

Carsuzaa

Marcy³

et al. 2021

Cancers

View full text Add to dashboard Cite

Radiotherapy plays an important role in the treatment of sinonasal cancer, mainly in the adjuvant setting after surgical resection. Many technological approaches have been described, including intensity-modulated radiotherapy, concomitant chemoradiotherapy, charged particle therapy or combined approaches. The choice is based on general criteria related to the oncological results and morbidity of each technique and their availability, as well as specific criteria related to the tumor (tumor extensions, pathology and quality of margins). The aims of this review are: (i) to provide an overview of the radiotherapy techniques available for the management of sinonasal malignant tumors and (ii) to describe the constraints and opportunities of radiotherapy owing to the recent developments of endonasal endoscopic surgery. The indication and morbidity of the different techniques will be discussed based on a critical literature review.

show abstract

Sinonasal cancers treatments: state of the art

Ferrari¹,

Orlandi

Bossi

2021

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewThe present review provides the reader with the state-of-the-art concepts of sinonasal oncology in view of the latest literature data.Recent findingsMost recent publications in sinonasal oncology assessed treatment timing, centralization, surgical approach, margin status, orbit/neck management, salvage strategies, emerging surgical technologies, intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), particle radiotherapy, and neoadjuvant chemotherapy.SummaryIndications to endoscopic surgery for sinonasal cancer have plateaued and are unlikely to further expand. Endoscopic surgery provides noninferior results compared to open surgery and best suits timing constraints imposed by multimodal treatment. Management of orbit-encroaching sinonasal cancer is remarkably improving mostly owing to optimal use of nonsurgical strategies. Prognostic value of the margin status and management of the nodal basin and recurrent sinonasal tumors are far from being fully elucidated. Most promising surgical technologies are surgical navigation, optical imaging, and radiofrequency-aided ablation. IMRT and VMAT have theoretical technical advantages that are in the process of being clinically demonstrated. Pieces of evidence are progressively confirming the physical and radiobiological advantages offered by particle radiotherapy. Systemic therapy is being tested mostly in the neoadjuvant setting with the aim of improving outcomes in locally advanced sinonasal cancers; response to induction chemotherapy could better select a further locoregional approach.

show abstract

Sinonasal Squamous Cell Carcinoma Outcomes: Does Treatment at a High-Volume Center Confer Survival Benefit?

Cited by 3 publications

References 0 publications

Case volume regionalization and volume‐based outcome differences in cutaneous head and neck melanoma

Case volume regionalization and volume‐based outcome differences in cutaneous head and neck melanoma

Precision Postoperative Radiotherapy in Sinonasal Carcinomas after Endonasal Endoscopic Surgery

Sinonasal cancers treatments: state of the art

Contact Info

Product

Resources

About